Compare Aurora Cannabis Inc (ACB) vs iShares Russell 2000 ETF (IWM) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

IWM, the iShares Russell 2000 ETF, trades at $301.53, up 1.11% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks US small-cap stocks, which have shown strong performance in 2026, though financial ratios are not applicable as it is a fund. Recent news highlights institutional inflows and small-cap outperformance versus large caps.

Outlook for IWM is positive due to small-cap strength and institutional support, but risks include higher volatility and competition from alternative ETFs. The bullish trend may continue if economic conditions favor small companies, though overbought RSI levels suggest potential near-term pullbacks.